Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Foradil Higher-Dose Phase IV Studies Slated For Completion By 2003

Executive Summary

Novartis will study higher doses of Foradil (formoterol) as a postmarketing commitment associated with FDA's Feb. 16 approval of the asthma therapy.
Advertisement

Related Content

Schering-Plough Puffs Up Asthma Line With Foradil From Novartis
Schering-Plough Puffs Up Asthma Line With Foradil From Novartis
Novartis Foradil Heart Monitoring Phase IV Required With COPD Approval
Novartis Foradil Heart Monitoring Phase IV Required With COPD Approval
AstraZeneca Symbicort U.S. Filing Awaits Results of Formoterol Trials
AstraZeneca Symbicort U.S. Filing Awaits Results of Formoterol Trials
Advertisement
UsernamePublicRestriction

Register

PS037366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel